Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California
Asterias Biotherapeutics Granted Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
CORRECTED: CHARBONE Hydrogen is Acquiring Hydrogen Production Assets and Closing a First Tranche of $1M Private Placement Financing
CORRIGE: CHARBONE Hydrogene acquiert des actifs de production d'hydrogene et cloture une premiere tranche d'un financement par placement prive de 1 M$
